Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Completed NA INTERVENTIONAL NCT01764230

Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Chemotherapy as one of the basic modalities of oncology treatment often leaves permanent implications and among the most common is infertility as a result of irreversible gonadal damage. This project sets the primary target to verify the protective effect GnRH analogues administration to protect ovarian tissue during three different regimens of chemotherapy in patients with Hodgkin disease (HD) in reproductive age.

Detailed Description

During the first two years of the project duration the curative anti-tumorous combined treatment in fertile patients with Hodgkin disease diagnosis will be carried out. Patients are to be divided into three groups according to the clinical stage of the disease and treated with the three types of the chemotherapeutic regimens comparable with toxicity. Patients will receive GnRH analogues during the chemotherapy for the gonadal protection by the mechanism of foliculogenesis inhibition in pre-pubertal stage. At the end of successful treatment according to stated criteria the ovarian function of every patient will be repeatedly evaluated in relation with toxicity of chemotherapy used. These ovarian function results will be compared with control group of patients without gonadal protection, which reproductive functions will be evaluated according the same method.

Interventions

Name: triptorelin
Type: DRUG
Description: Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.

Primary Outcomes

Measure: Premature ovarian failure after chemotherapy
TimeFrame: 6 months after the end of chemotherapy
Description: Premature ovarian failure defined as levels of FSH over 15 IU/l in peripheral blood.
Measure: Premature ovarian failure after chemotherapy
TimeFrame: 12 months after the end of chemotherapy
Description: Premature ovarian failure defined as levels of FSH over 15 IU/l in peripheral blood.

Trial Information

NCT ID

NCT01764230

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Masaryk University

Last Updated

December 15, 2025